Antisense techniques have been employed for over 30 years to suppress expression of target RNAs. Recently, microRNAs (miRNAs) have emerged as a new class of small, non-coding, regulatory RNA molecules that widely impact gene regulation, differentiation and disease states in both plants and animals. Antisense techniques that employ synthetic oligonucleotides have been used to study miRNA function and some of these compounds may have potential as novel drug candidates to intervene in diseases where miRNAs contribute to the underlying pathophysiology. Anti-miRNA oligonucleotides (AMOs) appear to work primarily through a steric blocking mechanism of action; these compounds are synthetic reverse complements that tightly bind and inactivate the miRNA. A variety of chemical modifications can be used to improve the performance and potency of AMOs. In general, modifications that confer nuclease stability and increase binding affinity improve AMO performance. Chemical modifications and/or certain structural features of the AMO may also facilitate invasion into the miRNA-induced silencing complex. In particular, it is essential that the AMO binds with high affinity to the miRNA 'seed region', which spans bases 2-8 from the 5¢-end of the miRNA.
INTRODUCTION
In the past decade, microRNAs (miRNAs) have emerged as a novel class of potent regulatory molecules that are found in a wide variety of organisms in both the plant and animal kingdoms. These small, noncoding RNAs modulate gene expression at the post-transcriptional level and are responsible for regulating many biological processes including differentiation, 1 apoptosis, proliferation and cell-fate determination. 2 Considering the role miRNAs have in regulating these cellular processes, it is not surprising that dysregulation of miRNAs has been implicated in a variety of pathologies, such as inflammatory and autoimmune diseases, neurological disorders, 3 myocardial disease, 4 as well as several types of cancer. 5 Recently, evidence has shown that miRNAs also have a role in viral infections, which include invoking an antiviral response; alternatively, the viruses themselves can encode miRNAs or regulate endogenous host miRNAs, which aid in the infection process. 6, 7 There are currently 41000 putative miRNAs encoded in the human genome, and miRNAs are estimated to regulate up to 60% of protein-coding mammalian genes. 8 As the number of discovered miRNAs and their regulated targets continually increases, the biological importance of these small non-coding RNAs becomes more evident.
The biogenesis of single-stranded mature miRNAs occurs via several processing steps. Primary miRNA transcripts, containing hairpin structures encoding mature miRNAs, are first transcribed in the nucleus. The hairpin structures are excised by the RNase III enzyme Drosha into pre-miRNA intermediates B70 nt in length and exported out of the nucleus. The pre-miRNAs are further processed in the cytoplasm by the double-stranded endoribonuclease Dicer into imperfect miRNA duplexes containing the single-stranded B21-24 nt mature miRNAs. The mature miRNA is incorporated into the miRNA-induced silencing complex (miRISC), which directs the miRNA to its mRNA target in a sequence-specific manner for translational inhibition or mRNA degradation. In animals, the miRNA typically binds in the 3¢UTR of the target gene with imperfect complementarity. An mRNA may be modulated by several different miRNAs, and each miRNA may regulate several genes. 9, 10 Much can be learned about the function of specific miRNAs by artificially increasing their level of expression (using miRNA mimics) or by artificially reducing their level of expression (using anti-miRNA oligonucleotides (AMOs)). Reagents that 'knock-up' or 'knock-down' miRNAs may be valuable tools to treat disease states caused by pathologic dysregulation of miRNA expression. Here, we review the current strategies used to block miRNA function using synthetic oligonucleotides with a focus on the design of effective AMOs and the use of chemical modifications to improve function and potency. We review recent literature demonstrating successful miRNA inhibition both in vitro and in vivo, as well as some of the technical challenges associated with specificity and data interpretation.
INHIBITING miRNA FUNCTION WITH SYNTHETIC OLIGONUCLEOTIDES Design and chemistry of AMOs
The use of synthetic oligonucleotides to suppress miRNA function represents a new application of antisense technology. Antisense oligonucleotides (ASOs) have been in use for over 30 years to suppress mRNA expression and these methods are now being used to study small, non-coding RNAs. When targeting mRNA, different ASO designs can have very different mechanisms of action, ranging from steric inhibition of translation to directly causing degradation of the target RNA species (by endogenous RNase H or RNase L, for example). Although the first anti-mRNA ASOs employed were unmodified DNA, 11 it was quickly appreciated that synthetic oligonucleotides of this type are rapidly degraded by endogenous exo-and endonucleases present in serum and in the intracellular environment. Chemical modification can be used to alter the properties of synthetic oligonucleotides by conferring nuclease resistance, increasing binding affinity, aiding in cellular uptake and altering the ability to trigger a response by the innate immune system. As such, chemical modification usually has an important role in all gene-knockdown technologies that employ synthetic oligonucleotides, including antisense, RNA interference, ribozymes, and so on. Depending on the precise mechanism of action involved and the kind of target nucleic acids, optimized chemical modification strategies have been devised for both singlestranded ASOs 12 and for double-stranded small interfering RNAs (siRNAs). 13 Many of these same chemical modification strategies can be employed to improve function of synthetic oligonucleotides when used as AMOs. Site selection can pose challenges when designing ASOs and siRNAs used to target mRNAs; in this case, the targets are usually hundreds to thousands of bases long. In contrast, miRNAs are very short, usually only 21-24 bases long, so AMOs are usually designed to be a perfect reverse complement intended to base pair with the full miRNA and there is no 'site selection' process involved. Chemical modifications that enhance binding affinity allow for use of AMOs, which are shorter than the target miRNA; in this case, it is important that the shortened AMO binds to the 5¢-end of the miRNA, including the 'seed region' . The chemical modifications discussed in this review are shown in Figure 1 and examples of different chemical modification patterns and AMO designs are shown in Table 1 .
Like the original anti-mRNA ASO study, the first attempts to suppress miRNA function employed unmodified DNA oligonucleotides. Boutla et al. 14 reported studies where DNA AMOs (Table 1) were directly microinjected into Drosophila embryos, leading to inactivation of miRNAs 2 and 13. AMOs with DNA composition probably only worked in this context due to use of microinjection, which avoids exposure to serum nucleases during delivery. DNA oligonucleotides have not worked to suppress miRNA activity when cationic lipids or 'naked' transfection methods are employed. Two reports appeared in 2004 that employed 2¢-O-methyl RNA (2¢OMe) (Figure 1 ) oligonucleotides as AMOs. Meister et al. 15 described use of 2¢OMe oligonucleotides that were a perfect reverse complement to the target miRNA (Table 1) , reducing expression of miR-21 in HeLa cells; at the same time, DNA oligonucleotides showed no effect, presumably due to rapid degradation. The same strategy was shown to also block action of a synthetic siRNA. Similar findings were reported by Hutvagner et al. 16 around the same time, where 31mer 2¢OMe oligonucleotides were used to inhibit let-7 and synthetic siRNAs specific for luciferase in HeLa cells and in Caenorhabditis elegans.
The 2¢OMe RNA chemistry offers several advantages over DNA for use in AMOs. First, the binding affinity (melting temperature, or T m ) is substantially higher for duplex formation with RNA targets (the T m for a 2¢OMe:RNA duplex is higher than for a DNA:RNA duplex of the same sequence). 17 Second, use of 2¢OMe RNA impedes the ability of many nucleases to degrade single-stranded oligonucleotides compared with DNA. Nevertheless, 2¢OMe RNA oligonucleotides are not fully nuclease resistant and this can be problematic. For example, DNA oligonucleotides are rapidly degraded in liver microsomal extracts (which mimics an intracellular environment) whereas 2¢OMe oligonucleotides survive this treatment for at least 24 h, yet both 2¢OMe and DNA oligonucleotides are rapidly degraded in serum. 18 The primary nuclease in serum that degrades synthetic oligonucleotides is a 3¢-exonuclease. 19 These patterns of relative nuclease resistance/sensitivity suggest that 2¢OMe AMOs should show improved performance if measures were taken to block exonuclease activity. Both endo-and exonucleases degrade nucleic acids by cleaving the phosphate bonds between nucleotides. The phosphorothioate (PS) modification substitutes a sulfur atom for a nonbridging oxygen in the phosphate backbone (Figure 1 ), which blocks, or at least reduces, the ability of many nucleases to degrade this bond. PS modifications can be placed uniformly throughout a sequence or can be selectively placed at critical locations, leaving some unmodified phosphodiester (PO) linkages. However, the PS modification reduces binding affinity, lowering T m for 2¢OMe oligonucleotides duplexed with an RNA target by B0.25 1C per modified linkage, 20 which could be a drawback if high binding affinity is important for potency.
The next advance in AMO technology came from Krützfeldt et al. 21, 22 who employed 2¢OMe oligonucleotides with several PS bonds between the internucleotide linkages at each end of the molecule to defend against exonuclease attack (Table 1) . A cholesterol group was attached to the 3¢-end to assist with delivery in vivo; this specific design of AMO was called an 'antagomir' . The compounds were a perfect reverse complement to the miRNAs targeting miR-122, which is abundantly expressed in the liver, and miR-16, which is more ubiquitously expressed. The antagomirs were administered to mice by tail vein injection. The version made as a PS chimera (mixed PO/PS linkages) showed good efficacy, with the miR-16 antagomir demonstrating reduction of miR-16 levels in a variety of tissues. Administration of the miR-122 antagomir resulted in lowering of serum cholesterol levels in treated mice. Importantly, changes in gene expression levels for several genes thought to be regulated by miR-122 were demonstrated. These results validated that the 2¢OMe PS-chimera design is effective for miRNA knockdown, that this chemical composition has sufficient nuclease stability to survive naked intravenous administration (that is, without protection by complexation with a delivery vehicle, like a liposome or nanoparticle), and that the compound achieves sufficient uptake into target tissues for use without requiring any other delivery aid (albeit at a very high dose of 80 mg kg À1 ). Other groups using the antagomir design have also found it to be effective in vivo. For example, Thum et al. 4 demonstrated a role for miR-21 in controlling mitogen-activated protein kinase signaling in fibroblasts using miR-21 antagomirs in a murine cardiac fibrosis model system and Ma et al. 23 demonstrated a role for miR-10b in tumor metastasis using antagomirs and a murine mammary tumor model system. Krützfeldt 21 also tested 2¢OMe miR-122 AMOs having complete PS modification and these compounds did not show reductions in miR-122 levels. As mentioned previously, the PS linkage reduces binding affinity and it is thought that complete PS modification sufficiently lowers the T m of 2¢OMe oligonucleotides such that potency is compromised. This would imply that use of chemical modifications that increase T m beyond what is achieved using 2¢OMe RNA should increase AMO potency, so long as nuclease stability is maintained.
2¢OMe RNA is a natural sugar modification present in most organisms. Artificial 2¢ modifications have been developed, which confer both increased binding affinity and increased nuclease resistance to synthetic oligonucleotides. Some of these new chemistries have shown significant benefit in antisense and siRNA applications Chemical modification and design of AMOs KA Lennox and MA Behlke and perform better than the same compounds made using 2¢OMe RNA. Several of these newer 2¢-modified chemistries have been used in AMOs and show similar benefits. Esau et al. 24 described use of the 2¢-O-methyoxyethyl (2¢MOE) (Figure 1 ) modification in AMOs, where the oligonucleotides were fully 2¢MOE-PS modified ( Table 1 ). The 2¢MOE modification improves nuclease resistance and increases T m and has been shown to be more potent than 2¢OMe RNA when used in traditional anti-mRNA antisense applications. A library of uniformly modified 2¢MOE-PS AMOs was used in cultured adipocytes to identify miR-143 as a miRNA involved in adipocyte differentiation. AMOs of this same design were later shown to perform well in vivo in reducing miR-122 levels, 25 leading to a decrease in serum cholesterol levels as was previously demonstrated using 2¢OMe-PS chimeras. 21 Unfortunately, this modification is not available for use to the general scientific community at large. This same group later published a thorough report where the chemical composition of AMOs targeting miR-21 was systematically varied to optimize the choice of chemistry and modification patterns employed. 26 T m values for the AMOs against a synthetic miR-21 RNA target were experimentally measured and correlated with potency. AMOs were made using DNA, 2¢OMe, 2¢MOE, 2¢F and Locked nucleic acid (LNA) nucleotides ( Figure 1 ) in varying patterns, with or without PS-modified internucleotide linkages (Table 1) . Both the PO and PS versions of the 2¢OMe AMOs performed poorly whereas the 2¢MOE versions showed higher activity, even though both compounds showed similar T m values. The 2¢MOE-PO outperformed the 2¢MOE-PS designs in all comparisons. The 2¢F-PS AMO also showed high potency. This group later made improvements to 2¢F-modified AMOs, demonstrating that terminal modification with two 2¢MOE bases on each end (Table 1) improved function in an in vivo model system and was the preferred design. 27 In general, those compositions having high binding affinity and high nuclease resistance showed better performance, however, this correlation was not perfect and the LNA/2¢MOE-PS mixmer, which has the highest T m , was outperformed by several designs. Incorporation of T m -increasing chemical modifications, such as LNA bases, into an oligonucleotide such as an AMO will stabilize it when binding to a complementary target and will typically increase its ability to inhibit miRNA activity. However, sometimes it can also cause strong secondary structures to form within the oligonucleotide or increase self-dimerization potential depending on the sequence context, which can lower AMO potency (KA Lennox and MA Behlke, unpublished observation). This could be particularly detrimental to AMO potency if the self-dimerization or hairpin formation occurred in the region of the AMO that binds to the targeted miRNA seed region, which is comprised of bases 2-8 from the 5¢-end of the miRNA. Although secondary structure and self-dimerization predictions suggest that this is not the case for the AMO sequences in these experiments, there could potentially be something in the chemical composition of the LNA/2¢MOE-PS AMO that is prohibitive to miRISC invasion or annealing with the seed region of the targeted miRNA. 18 In anti-mRNA antisense applications, a 'gapmer' ASO design is routinely used, which triggers RNase H degradation of the target mRNA. This design employs a central domain of B10 PS-modified Table 1 Continued DNA residues flanked by high binding affinity 2¢-modified bases, with the DNA domain functioning as the RNase H activating region. 2¢MOE/DNA gapmers of this design were tested and showed poor performance as AMOs; the 'steric blocker' design appears to be preferred. 26 The lengths of the AMOs were varied and, in general, full-length or near full-length AMOs were more potent than shorter compounds using these chemistries. One exception to this rule was seen where shortening the AMO by one base from the 3¢-end (which would bind to the first 5¢-base of the miRNA, immediately before the start of the seed region) did slightly increase potency. When an AMO binds a target miRNA, a duplex is formed that is similar in some ways to a double-stranded siRNA. Many of the chemistries and modification patterns studied in AMOs were also tested for function when incorporated into the passenger strand in an anti-PTEN siRNA. Interestingly, those chemistries that performed well in AMOs performed poorly when used in siRNAs and designs that performed well in siRNAs performed poorly as AMOs. As part of the process of loading a siRNA into RISC, the passenger strand is either cleaved by Ago2 or is unwound and discarded (regardless of the mechanism, the passenger and guide strands must be separated). In general, potent AMO designs show resistance to nuclease cleavage and have high binding affinity, making it difficult to separate the AMO from the target miRNA by either cleavage or unwinding, consistent with a steric-blocking mechanism of action. LNAs have become a prominent modification employed in AMOs both in vitro and in vivo. LNAs are a bicyclic nucleic acid that tether the 2¢-O to the 4¢-C via a methylene bridge (Figure 1 ), effectively locking the structure into a 3¢-endo sugar conformation. 28, 29 This modification provides stabilization against nucleases and also offers the greatest increase in binding affinity of any of nucleic acid modifications in common use today, adding 1.5-6 1C per modification against an RNA target. One study examined the effect that 10 LNA substitutions had on the binding affinity of ASOs upon duplex formation with an RNA target and found that the LNA modifications gave a 24 1C T m increase compared with a DNA control when a PO backbone was used (an average of +2.4 1C per modification) and 16 1C when using a PS backbone (an average of +1.6 1C per modification). 20 Chan et al. 30 first described the use of LNA nucleotides in AMOs in 2005 with an LNA-modified anti-miR-21 compound that had a central core of eight LNA nucleotides flanked on each side by seven DNA bases. This design worked slightly better than a uniformly modified 2¢OMe AMO; however, given the nuclease sensitivity of the two DNA domains, it may be that the actual active compound in cells following transfection was the nuclease-resistant core 8mer LNA domain ( Table 1 ). The same DNA/LNA/DNA designs were later used by Naguibneva et al. 31 to suppress miR-181 expression in mouse myoblasts. Orom et al. 32 described use of AMOs that were fully LNA modified (Table 1) , demonstrating knockdown of bantam miRNA in Drosophila cells. Although the LNA modification increases binding affinity against an RNA target, LNA:LNA hybrids show an even higher T m ; as such, 21-23mer AMOs that are fully LNA modified often form stable hairpin and self-dimer structures that can interfere with function (KA Lennox and MA Behlke, unpublished observation).
One way around this problem is to intersperse DNA or other nucleotide types between LNA bases. In fact, this kind of LNA/DNA mixmer is the standard probe design employed for in situ hybridization experiments to detect miRNA species in histology. 33, 34 Typically, the probes used in these methods employ a repeating pattern of two DNAs followed by one LNA nucleotide and incorporate seven LNAs in a 21-23mer probe. The relative potency of a variety of AMO designs using a miR-21 reporter system were directly compared by Lennox and Behlke 18 and LNA mixmers were among the most potent designs tested (Table 1) . LNA/DNA mixmers with a PO backbone were found to degrade in serum, whereas PS end-blocked chimeras or fully PS-modified versions were stable for at least 24 h. The most potent design tested was an LNA/2¢OMe mixmer (repeating unit of two 2¢OMe and one LNA nucleotide), however this design also showed decreased specificity relative to the less potent, lower binding-affinity compounds (specificity will be discussed in greater detail later in this review). Fabani and Gait 35 described a miR-122 LNA/2¢OMe mixmer AMO that had 10 LNA bases and 13 2¢OMe bases with a PO backbone ( Table 1) . Like the anti-miR-21 mixmers, this compound showed a significant increase in potency when compared with lower-affinity designs, such as a uniform 2¢OMe AMO.
Given their very high affinity, LNA-modified AMOs can also be made shorter than the target miRNA and retain high potency. In fact, the shorter versions of the LNA AMOs may have distinct advantages, having higher specificity and better in vivo tissue delivery than their full-length counterparts. Elmen et al. 36 described use of a 16mer LNA/ DNA AMO that was fully PS modified to suppress miR-122 in mice (Table 1 ). This compound used the repeating motif 'two DNA-one LNA' pattern as was originally employed in the in situ hybridization probes and comprised 11 DNA and 5 LNA nucleotides. Most notably, this design showed B10-fold higher potency with intravenous administration than the original miR-122 antagomir reported in 2005 (using a 2¢OMe-PS chimera+cholesterol chemistry). 21 When designing AMOs that are shorter than the target miRNA, truncation is preferably done at the 5¢-end of the AMO sequence (corresponding to the 3¢-end of the miRNA target) so that when hybridized, the AMO fully spans the miRNA seed region.
While use of a fixed modification pattern is convenient for the manufacture of AMOs against many targets, the modification pattern can be optimized for individual sequences when the cost to perform the optimization studies is justified by the value of the target. As part of preclinical studies on LNA/DNA-PS AMO drug candidates, Santaris Pharma (Hørsholm, Denmark) optimized the chemical composition of their anti-miR-122 compound. The improved version was a 15mer comprising seven DNA and eight LNA nucleotides, also fully PS modified (Table 1) . 37 This compound was administered to non-human primates (African green monkeys, Chlorocebus aethiops) by intravenous injection. The LNA/DNA-PS AMO was given every other day for a total of three injections at doses ranging from 1 to 10 mg kg À1 . In the high-dose cohort, free miR-122 levels were substantially reduced in RNA isolated from liver biopsies and total plasma cholesterol decreased by 40%, reaching a nadir 3 weeks after the first dosing. A decrease in plasma cholesterol levels was detected for over 3 months following the last dose. Thus, once again the short LNAmodified miR-122 AMOs showed significantly higher potency than the original 2¢OMe-PS-Chol chimera antagomir, which required dosing at 80 mg kg À1 to achieve a similar response in mice. 21 In addition to a role in regulating cholesterol metabolism, miR-122 has been implicated as an important host factor in Hepatitis C Virus (HCV) infection. Two putative miR-122 binding sites exist in the viral RNA and miR-122 binding results in upregulation of RNA levels. Interaction of endogenous miR-122 with the viral RNA appears to be required for effective maintenance of infection, and interfering with miR-122 function may offer a new avenue to treat HCV. The same optimized miR-122 LNA/DNA-PS AMO described above was studied for efficacy as an anti-HCV therapy. 7 HCV-infected chimpanzees were administered this AMO at a dose of 1 or 5 mg kg À1 with weekly intravenous injection for 12 weeks followed by a 17-week recovery period. HCV RNA levels dropped by as much as 400-fold in the high-dose cohort and remained suppressed by 10-fold 16 weeks after discontinuation of treatment. Thus, inhibitors of miR-122 may have a therapeutic role in both the treatment of HCV infection as well as hypercholesterolemia.
An optimized LNA/DNA-PS AMO targeting miR-155 has also been reported; this compound was a 15mer with 10 LNA and 5 DNA nucleotides (Table 1) . 38 The miR-155 AMO was administered to mice via intravenous injection on three consecutive days at a dose of 25 mg kg À1 . Mice were given bacterial lipopolysaccharide to trigger an innate immune response. Animals given the miR-155 inhibitor showed derepression of the transcription factor C/EBP beta with lowering of G-CSF levels, suggesting that miR-155 AMOs may be useful as anti-inflammatory agents.
In some circumstances, it may be desirable to inhibit entire families of miRNAs. miRNA family members tend to regulate the same genes through their shared seed region sequences. To address this, Obad et al. 39 recently described the use of short 8mer fully-LNA-PSmodified AMOs (Table 1) , which bind solely to the seed region of the targeted miRNA. These 'tiny LNAs' were validated to effectively inhibit the function of both individual miRNAs (miR-21) as well as entire families of miRNAs (miR-221/222 and let-7) in cell culture using a luciferase-based detection method. Even though these tiny LNAs have an increased number of perfect matched recognition sequences in the transcriptome that may lead to off-target effects, specificity was maintained. Additionally, binding other regions of the miRNA outside of the seed region was ineffective at inhibiting miRNA function. Following in vitro validation, a 35 S-labeled tiny LNA miR-21 AMO was administered naked intravenously to mice at 10 mg kg À1 dose with biodistribution analysis demonstrating uptake in a wide variety of tissues. In vivo inhibition of miR-122 was achieved with three intravenous doses of 20 mg kg À1 tiny LNA AMO in mice over a 7-day period, lowering plasma cholesterol levels and significantly derepressing genes regulated by miR-122. This study emphasizes the importance of the seed region in miRNA activity. Further, the limited function of tiny LNA AMOs targeting positions other than the seed region provides insights into possible structural constraints associated with miRISC-loaded mature miRNAs that may hinder AMO binding. Alternatively, the tiny LNA AMOs specific for non-seed region sequences on the miRNA may be ineffective if the exposed seed region alone is sufficient enough to promote binding to and downregulation of the target mRNA.
The AMO designs discussed above all employ nucleotide modifications that improve binding affinity and nuclease stability; most are of the same length or shorter than the target miRNA. Vermeulen et al. 40 recently described the use of double-stranded domains and hairpin structures in 2¢OMe AMOs that substantially increased potency over traditional single-stranded linear designs using the same chemistry. Each AMO had a centrally placed domain that was a perfect reverse complement to the target miRNA, and a variety of different sequences were added on both ends. The most potent design variant was a 54mer that had a 16-base domain on each end, which comprised a hairpin structure having a 6-base stem with a 4-base loop (Table 1) . Terminal hairpin structures have been used in the past to successfully stabilize 2¢OMe anti-mRNA ASOs and improve potency. 41 In the present application, the hairpin ends both block exonuclease attack and increase binding affinity through the base stacking interactions that occur when the target miRNA hybridizes into the dumbbell structure. The increase in potency seen using this method was higher than anticipated from these effects and the authors of this study speculated that the double-stranded motifs assisted in invasion of the AMO into miRISC, improving its ability to bind a miRNA already within the complex. We similarly observed that this dumbbell design increases potency well above that seen with otherwise unmodified linear 2¢OMe AMOs. 18 Non-nucleotide chemical modifiers can also be used to increase AMO potency. Lennox et al. 20 have developed a napthyl-based chemical modifying group that increases binding affinity and blocks exonuclease attack when placed between terminal nucleotides; the greatest benefit is seen when one modifier is placed near each end (KA Lennox and MA Behlke, manuscript in preparation). This modifier increases the potency of linear 2¢OMe PO AMOs to the level seen with LNA/DNA-PS mixmers with increased specificity and reduced toxicity in vitro. Hornstein and colleagues 42 used AMOs of this new design (Table 1) to inhibit a variety of miRNAs in pancreatic tissue, demonstrating roles for miRNAs 24, 26, 148 and 182 in insulin production.
All of the AMOs discussed employed chemical modifications based on a ribose nucleic acid backbone. Other non-natural chemical backbones have been described that show good potency when used as steric-blocking ASOs, such as peptide nucleic acids (PNAs) or phosphorodiamidate morpholino oligonucleotides (PMOs) (Figure 1 ). These chemistries are extremely nuclease resistant but, unlike natural nucleic acids, are charge neutral, so handling and delivery can be a challenge. Fabani and Gait 35 described use of a PNA AMO against miR-122 that had an amino-terminal cysteine to facilitate conjugation and four lysine residues to confer charge ( Table 1 ). The PNA was delivered into cells using electroporation or was conjugated to the cell-penetrating peptide 'Penetratin' , which permitted direct delivery into cells in tissue culture without any additional delivery aid. Both methods successfully suppressed functional miR-122 levels. The same PNA AMO designs were later used by Fabani to target miR-155 in mice. 43 Mice were given two doses of the miR-155 PNA AMO at 50 mg kg À1 by intraperitoneal injection and splenocytes were examined for miR-155 levels after lipopolysaccharide stimulation. Not only were miR-155 levels reduced, but gene expression profiles in splenic B-cells (using microarray analysis) appeared similar in the miR-155 PNA AMO-treated mice as in control miR-155 À/À knockout mice, and both of these profiles were very different from gene expression profiles seen in wild-type mice. Interestingly, in vivo delivery to splenic B-cells was achieved without conjugation with a cell-penetrating peptide or use of any other transfection aid.
PMOs have been used for many years as steric blocking antisense agents 44 and have found particular utility in the Zebrafish system, where direct microinjection into embryos is the method of choice to study gene function. 45 Not surprisingly, PMOs have also proven to be effective anti-miRNA compounds in Zebrafish. Flynt et al. 46 reported knockdown of miR-214 in Zebrafish, demonstrating a role for this miRNA in muscle cell development. Like PNAs, neutral PMOs are difficult to use with mammalian cells. PMOs can be conjugated to cell-penetrating peptides to facilitate delivery, which can work in both tissue culture and in vivo. A new delivery method was recently described where a dendrimer bearing eight guanidinium groups was conjugated to the PMO, which promoted uptake into mammalian cells. 47 PMO conjugates of this design can be administered to mice by intravenous or intraperitoneal injection and penetrate a wide range of tissues; the availability of this new delivery method may enable more widespread use of AMOs made from this interesting chemistry.
Specificity
It is important to understand the specificity of any reagent employed in gene-knockdown studies. As a general rule, modifications that increase binding affinity also make an oligonucleotide more likely to hybridize to a mismatched target. It may be necessary to adjust the length and modification content of an oligonucleotide (that is, to adjust T m ) to achieve the desired balance between potency and specificity. From a practical standpoint, sometimes crossreactivity problems seen in an in vitro setting where high oligonucleotide concentrations are easily achieved are reduced when used in vivo, where high intracellular oligonucleotide concentrations are seldom seen. Thus, specificity should be studied in the actual system of interest and results cannot always be generalized between model systems.
Krützfeldt 22 studied the specificity of a miR-122 antagomir (2¢OMe-PS chimera with 3¢-cholesterol) in mice. The presence of two or four mismatches with the target completely eliminated knockdown of miR-122. A single mismatch had variable effect depending on the location of the mismatch; a mismatch at position 19 completely eliminated knockdown while a mismatch at position 11 showed partial knockdown and a mismatch at position 1 showed complete knockdown of the target. Note that this AMO design is not modified with potent T m -enhancing modifications (such as LNAs) and thus would be predicted to show relatively high specificity. Davis studied the effects of various mismatches on the ability of a 2¢MOE AMO to reduce miR-21 expression using a reporter assay in HeLa cells. 26 This modification has somewhat higher binding affinity than 2¢OMe RNA against an RNA target. A single mismatch reduced but did not eliminate activity, especially at high dose (100 nM), whereas two or more mismatches essentially blocked activity of this class of AMO.
Lennox and Behlke 18 studied the effect of mismatches on specificity of several different miR-21 AMO designs using a reporter system in HeLa cells. Not surprisingly, the ability of mutated AMOs to reduce the expression of miR-21 varied with dose and with chemical composition. The LNA/2¢OMe-PS mixmer had the highest T m of any of the AMOs studied, and, while extremely potent, had the lowest specificity; even with three mismatches present, detectable knockdown of miR-21 was seen at high dose (50 nM). The LNA/DNA-PS mixmers showed better specificity, but knockdown of miR-21 was still detected with two mismatches present. Even the 2¢OMe AMOs (which had the lowest T m of any of the compounds studied) showed some miR-21 knockdown in the presence of a single mismatch when used at high dose (50 nM) (KA Lennox and MA Behlke, manuscript in preparation). High-affinity modifications like LNAs can still show high specificity if the AMOs are shortened. The miR-21 AMOs studied by Lennox were full-length reverse complements (22mers). In contrast, the 16mer anti-miR-122 LNA/DNA-PS mixmer studied by Elmen et al. 36 showed no target knockdown in mouse livers when two mismatches were present. For this short sequence, the T m of the LNA/DNA-PS AMO against a synthetic miR-122 RNA target was measured to drop from 69 to 46 1C with the introduction of two mismatches.
Robertson et al. 48 performed a large, comprehensive study where dinucleotide mutations were systematically introduced in a 'walk' along with an AMO to assess positional effects of mismatches for AMO function using a reporter assay. Three miRNA targets were studied, including miR-21 and miR-22 (in HeLa cells) and miR-122 (in Huh7 cells). 2¢OMe AMOs with terminal hairpin domains were employed. 40 From a thermodynamic standpoint, mutations in the center of a 22mer sequence usually destabilize duplex formation to a much greater extent than mutations located near the ends. Interestingly, the effect of mutations on AMO function did not track this way. Instead, mutations placed at the center of the AMOs (corresponding to bases 9-12 of the miRNA) and the 5¢-ends (bases [19] [20] [21] [22] [23] showed relatively little impact on AMO potency whereas mutations placed in the 3¢-end (bases 3-8) and off-center to the 5¢-side (bases [13] [14] [15] [16] [17] [18] showed much greater effects. The 3¢-domain of the AMO pairs with the 5¢-end of the miRNA where the seed region is located; bases 2-8 are most critical for determining miRNA specificity. Thus, it appears that the impact of mismatches on AMO function may track better with the location of functional domains within the miRNA and not classical thermodynamic considerations.
In general, most users are better served by having reagents with high specificity. However, there are some circumstances where having compounds that crossreact between related species is desirable. For example, a high-affinity AMO with reduced specificity (such as the LNA/2¢OMe mixmer), which is the reverse complement to a fulllength 'consensus sequence' , could target an entire miRNA family. Alternatively, the clever approach used by Obad et al. 39 effectively utilized the high-affinity LNA modifications in short AMOs complementary to the seed region to knockout the let-7 and miR-221/222 families of miRNAs. This strategy obviates the challenges associated with designing a full-length AMO nonspecific enough to include all of the intended miRNA family members whereas specific enough to eliminate other off-target events.
Problems with quantifying miRNA levels when using AMOs AMOs are administered to reduce expression of a specific miRNA, which causes changes in gene expression, which in turn eventually results in changes in phenotype. Alterations in gene expression profiles and phenotype are far downstream from the primary biochemical trigger event, which is binding of the miRNA by the AMO. AMO/ miRNA binding directly causes a reduction in functional miRNA levels-but are miRNA levels actually reduced or are the miRNAs simply bound by the AMO and removed from the functional intracellular pool? Many investigators have reported reductions in miRNA levels following AMO treatment using Northern blots, qPCR or other methods. Unfortunately, the results from these methods may be influenced by the presence of the AMO, so it can sometimes be difficult to distinguish real changes in miRNA levels from artifacts. AMOs are usually made using chemical modifications that increase binding affinity, and their binding affinity can be high enough that standard methods to disrupt the miRNA and AMO interaction fail, so that the AMO remains bound to the miRNA and interferes with detection assays. Krützfeldt et al. 21 described use of polyacrylamide gels with 8 M urea and 20% formamide for Northern blot experiments to study the effects of 2¢OMe antagomirs on miR-122 levels. Note that these compounds (2¢OMe-PS chimeras) have lower binding affinity than AMOs made with 2¢F, 2¢MOE or LNA modifications and that this approach might be inadequate to ensure denaturation of the miRNA/ AMO complex. As a further complication, Davis et al. 27 observed that the chemical composition of the AMO can influence recovery of oligonucleotides and/or complexes when using the organic solvent RNA purification methods, which are usually employed to isolate small RNA species (such as Trizol). Their results found that the AMO/ miRNA complex, for AMO modifications such as LNA, partitioned into the discarded organic phase during the RNA extraction process. Torres et al. 49 recently confirmed that certain AMO/miRNA complexes were not recovered when using organic solvents for RNA extraction, conversely demonstrating that the small RNAs were retained in the isopropanol fraction during precipitation. They revised the RNA isolation process, finding that increasing the isopropanol volumes during precipitation could recover the miRNA/AMO complexes.
To improve accuracy of miRNA assays in the presence of AMOs, Davis et al. 27 developed a method of using high-affinity PNA compounds to block the AMO before performing miRNA quantification assays. A PNA was made with the same sequence as the target miRNA; the RNA sample was heated at 95 1C to denature pre-existing miRNA/AMO complexes in the presence of excess PNA competitor, and after cooling the AMO hybridized with the PNA, leaving the miRNA unbound and available for hybridization with a detection probe. The uncharged PNA migrates at a very different location during gel electrophoresis than the miRNA, so any signal arising from free PNA is easily distinguished from true positive signals resulting from the miRNA in Northern blots. Using this technique, they demonstrated that a 2¢F/2¢MOE AMO showed evidence for potent functional knockdown of miR-122 in mice without a substantial reduction in actual miRNA levels. Torres et al., 49 in conjunction with the improved RNA extraction protocol mentioned above (using higher isopropanol equivalents), employed the PNA decoy method to demonstrate that use of a K-PNA-K3, LNA/DNA or LNA/2¢OMe mixmer AMOs does not lead to degradation of the target miRNA when bound in miRISC, whereas use of a lower binding affinity 2¢OMe-modified AMO does lead to degradation of the miRNA when targeting miR-122 in Huh7 cells.
The fate of the miRNA/AMO duplex has been a point of contention due to the assay complications just discussed, and many of the earlier studies suggesting AMOs can degrade miRNAs may need to be re-evaluated. The improvements made to recover and more accurately detect miRNA levels have already suggested that fate is determined by the chemical composition of the AMO. Whether this has clinical implications has yet to be determined. From a therapeutic standpoint, it may be advantageous to use a chemical compound that degrades a targeted miRNA versus one that sequesters it. Degradation of the miRNA should allow miRISC to be recycled, maintaining the appropriate miRISC levels found in a healthy cell. If sequestering the miRNA also sequesters the miRISC bound to the AMO/miRNA complex, functional miRISC levels will be reduced, which may cause detriment to the cell.
CONCLUSIONS
AMOs represent an important new application of antisense technology. AMOs are already very useful tools in dissecting miRNA function and may also prove to be candidates for drug development in cases where overexpression of particular miRNAs are associated with disease states. As in any antisense application, the use of chemical modifications has a large impact on the potency and specificity of the ASO. Generally speaking, chemical modifications that increase binding affinity also increase potency. In several of the reports discussed above, addition of high-affinity chemical modifications, such as LNA or 2¢F bases, significantly improved AMO efficacy. Our own studies suggest that, up to a point, there is a good correlation between AMO T m and in vitro potency (Lennox and Behlke, manuscript in preparation). However, after a certain point this correlation falls off, as if a critical level of binding affinity must be reached, after which further increasing the T m of the AMO only serves to lower specificity and additional gains in potency are not achieved.
What features comprise a good AMO design? An AMO binds tightly to its target, the mature miRNA, thereby eliminating this species from functionally participating in gene suppression via miR-ISC. The AMO:miRNA complex is a duplex nucleic acid. Mature natural miRNAs start as a double-stranded species and are rendered single stranded within miRISC. Routes available for the miRNA to become single stranded include cleavage of the passenger strand by Ago2 (as in the siRNA pathway) or unwinding and discarding the passenger strand by the action of an RNA helicase. For an AMO to be effective, it must evade the natural pathways available to the miRNA guide strand to convert from double-stranded to single-stranded form. Thus, the AMO must be nuclease stabilized (to evade degradation by Ago2 as well as to survive transfection) and must have sufficient binding affinity to prevent unwinding by a helicase activity. With this in mind, there is likely a T m threshold below which increasing the binding affinity is beneficial to AMO potency; once helicase unwinding is fully prevented, a plateau is reached after which any additional T m increases will only serve to increase the chance for off-target effects. Obviously, this proposed threshold T m will vary with sequence and will be affected by intracellular AMO concentration. It is also important to remember that the seed region drives the miRNAtarget mRNA interaction so it is essential that the AMO:miRNA duplex structure includes these critical bases; this is best evidenced by the surprising efficacy of the tiny LNAs that bind only to the seed region. 39 Additional factors may contribute to the functional potency of an AMO. In particular, it may be advantageous for the AMO to invade miRISC and inactivate pre-existing miRNA:miRISC complexes. It is not certain what factors improve the ability of an AMO to invade miRISC. 2¢OMe dumbbell-shaped AMOs show potency higher than would be predicted from just the nuclease end stabilization imparted by the terminal hairpins in this structure, and the inventors of this design speculate that the improved performance is in part related to improved ability of this structure to invade miRISC. 40 Shorter AMOs may also invade miRISC easily, which may contribute to the efficacy of the tiny LNA class of compounds. 39 Along these lines, AMOs with 3¢ nucleotide truncations were seen to improve efficacy in one study, potentially by avoiding hypothetical structural constraints associated with the Piwi-binding domain, thereby allowing improved access of the AMO to the targeted miRNA. 26 Specificity is an important consideration when designing AMOs and the degree of stringency desired can vary with the experimental goals. As expected from basic thermodynamic principles, AMOs with a high T m , such as those that incorporate LNA modifications, often show activity even when one or two mismatches are present between the AMO and its target miRNA. The degree of crossreactivity is also highly dependent on mismatch placement (that is, mismatches in the seed region are more disruptive to AMO function). Selecting a modification pattern that confers a lower T m may be appropriate when high specificity is desired. Additionally, the ability of an AMO to bind to mismatched targets increases with concentration, so using the lowest effective dose in a given experiment will also help ensure greater specificity. Of course, increasing specificity by reducing binding affinity and using lower doses comes at the expense of lower AMO potency; however, this may sometimes be a necessary compromise to attaining the level of specificity needed for certain applications.
In summary, there is no single 'best' modification pattern or design to employ in AMOs. A number of good options exist and choice of chemistry should be guided by the needs of each experimental setting.
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